Archive | May, 2014

Colchicine for Recurrent Pericarditis

In a new trial (Lancet March 30, 2014), colchicine, was found to be safe and beneficial adjunct to nonsteroidal anti-inflammatory drugs, even in patients with multiple recurrences.  Previous trials have demonstrated the efficacy and safety of colchicine as an adjunct to conventional treatment in patients with acute pericarditis or first recurrences. To assess whether colchicine’s […]

Leave a comment Continue Reading →

β blockers for Heart Failure: Which One Should You Use?

β blockers are a cornerstone of the medical management of heart failure. The long term use of certain β blockers in patients with heart failure reduces hospital admissions and improves symptoms, quality of life, and survival. However, it is still unclear whether this is a class effect or whether one β blocker is superior to […]

Leave a comment Continue Reading →

Effect of ACE Inhibitors and ARBs on Cardiovascular Outcomes in Diabetes

A recent meta-analysis, published in JAMA Intern Med on March 31, 2014, analyzed the effect of ACE inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) on all-cause mortality, cardiovascular (CV) deaths, and major CV events in patients with diabetes mellitus (DM). The authors of this study included randomized clinical trials reporting the effects of ACEI […]

Leave a comment Continue Reading →

FDA: Does Not Recommend Using Aspirin for Primary Prevention of Heart Attack or Stroke

Aspirin should not be used to prevent a first heart attack or stroke in patients with no history of cardiovascular disease, according to the U.S. Food and Drug Administration (FDA). In a statement released on May 5, 2014, the FDA said that its review of available data does not support the use of aspirin for […]

Leave a comment Continue Reading →